IBRUTINIB

SynDRA canonical compound SYN0027951 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	BTK
Mechanism of action	BTK inhibitor
Indication	chronic lymphocytic leukemia (CLL) \| mantle cell lymphoma (MCL) \| Waldenstrom's macroglobulinemia (WM)
Disease area	hematologic malignancy

All known targets

imbruvica
PCI-32765
CRA-032765
PCI-32765-00
Imbruvica
PC-32765
Ibrutinib (BTK inhibitor)
PCI 32765
IMBRUVICA
Ibrutinib (PCI-32765)
PCI-32765 (Ibrutinib)
CRA 032765
Pc-32765
(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
1X70OSD4VX
CHEBI:76612
PCI32765
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one
2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-
(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one
Ibrutinib [USAN]
Ibrutinib [USAN:INN]
UNII-1X70OSD4VX
ibrutinibum
JNJ 02
Imbruvica (TN)
Ibrutinib- Bio-X
IBRUTINIB [INN]
IBRUTINIB [JAN]
IBRUTINIB [MI]
Ibrutinib (JAN/USAN)
IBRUTINIB [VANDF]
IBRUTINIB [WHO-DD]
Imbruvica; PCI-32765